Novo Nordisk Increases 2026 Financial Forecasts After Launch of Oral Wegovy
Introduction
Novo Nordisk has raised its profit and sales predictions for 2026. This decision follows the strong early success of its oral weight-loss medication, the Wegovy pill, in the United States.
Main Body
The company reported first-quarter sales of 96.8 billion Danish kroner, which is a 32% increase and higher than analysts expected. Operating profit also grew by 65% to 59.6 billion kroner. However, when excluding a one-time $4.2 billion adjustment related to a U.S. pricing program, adjusted sales and profits actually fell by 4% and 6% respectively. Despite this, the oral version of Wegovy earned 2.26 billion kroner in its first quarter. With over two million prescriptions, the company emphasized that this was the most successful launch of a GLP-1 drug in the U.S. However, Novo Nordisk faces strong competition from Eli Lilly, which now has a larger market share in injectable weight-loss treatments. While Eli Lilly recently launched its own pill, Foundayo, it has not yet reached the same sales volume as Wegovy. At the same time, some investors are worried about Novo Nordisk's future products. For example, trial data suggested that a new drug called CagriSema was less effective than Lilly's Zepbound, which caused the company's share price to hit a five-year low. To address these challenges, CEO Mike Doustdar stated that the company will focus more on business development and buying other companies to expand its range of treatments. The management team asserted that their current projects remain strong. Furthermore, the company is monitoring how the new pill affects sales of its injectable versions, as it is not yet clear if patients will simply switch from one format to the other.
Conclusion
Novo Nordisk has improved its 2026 outlook due to the popularity of its oral obesity treatment, while also seeking new acquisitions to stay competitive against Eli Lilly.
Learning
🚀 The 'Bridge' to B2: Mastering Contrast & Nuance
At the A2 level, you likely use but for everything. To reach B2, you need to signal contrast more precisely. This article is a goldmine for this because business news isn't just about success; it's about the tension between 'good news' and 'bad news'.
⚡ The Upgrade Path
Instead of saying: "The sales are high, but the profits fell." Try using these 'B2 Signal Words' found in the text:
- However Used to introduce a surprising opposite point.
- Example from text: "Operating profit also grew... However, when excluding [costs], profits actually fell."
- Despite this Used to show that something happened even though there was a problem.
- Example from text: "...profits actually fell... Despite this, the oral version of Wegovy earned 2.26 billion."
- While Used to compare two different situations at the same time.
- Example from text: "While Eli Lilly recently launched its own pill... it has not yet reached the same sales volume."
🛠️ Linguistic Logic: The 'Switch'
Notice how the author moves from Positive Negative Action.
- Positive: Sales are up 32%.
- Negative (The Contrast): But wait, some trial data was bad, and the share price hit a low.
- Action (The Solution): To address this, the CEO will buy other companies.
B2 Tip: When you speak or write, don't just list facts. Use However or Despite this to show the listener that you are analyzing the situation, not just translating words. This is the primary difference between a basic speaker (A2) and a fluent communicator (B2).